Neural basis of cognitive control symptoms in schizophrenia

Neural basis of cognitive control symptoms in schizophrenia - Cognitive control in schizophrenia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38640

Enrollment

Registered

2013-11-12

Start date

2014-01-22

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia psychosis

Interventions

None listed

Eligibility

Age

12 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1) Must be between the ages of 18-55 2) Schizophrenia patients: must have a diagnosis of schizophrenia or schizoaffective disorder 3) Schizophrenia patients: must be stablized on psychotropic medications 4) Healthy first-degree relative: must have a first-degree relative with schizophrenia or schizoaffective disorder 5) Be mentally competent, as determined by their treating physician. 6) Provide written informed consent.

Exclusion criteria

Exclusion criteria: 1) Non-removable metal objects in head/body 2) pregnancy 3) history of closed or open head injury with loss of consciousness 4) personal history of psychiatric illness (in healthy first-degree relatives and healthy non-relatives) 5) history of neurological illness 6) use of psychotropic medications in healthy controls and relatives 7) substance abuse or dependence within the preceding 6 months (except nicotine) 8) claustrophobia 9) history of schizophrenia in first-degree family members of healthy non-relative controls

Design outcomes

Primary

Measure	Time frame
In general, our main study endpoints will be differences between patients with schizophrenia, healthy first-degree relatives of schizophrenia patients, and demographically-matched healthy controls. Specifically, we are interested group differences for the following measures and their relationships with symptom severity and employment status: 1. Performance on the search-step task, including efficiency of response inhibition (TSRT) and changes in reaction time as a function of trial history. 2. Functional MRI activation measures in several regions of interest 3. Differences in structural connectivity between regions of interest using DTI 4. Lactate and GABA levels measured using 1H-MRS and their correlations with performance on the search-step task.	—

Measure

Time frame

In general, our main study endpoints will be differences between patients with schizophrenia, healthy first-degree relatives of schizophrenia patients, and demographically-matched healthy controls. Specifically, we are interested group differences for the following measures and their relationships with symptom severity and employment status: 1. Performance on the search-step task, including efficiency of response inhibition (TSRT) and changes in reaction time as a function of trial history. 2. Functional MRI activation measures in several regions of interest 3. Differences in structural connectivity between regions of interest using DTI 4. Lactate and GABA levels measured using 1H-MRS and their correlations with performance on the search-step task.

—

Secondary

Measure	Time frame
Relationship between employment status and cognitive control measures	—

Countries

Netherlands

Outcome results